Literature DB >> 23953913

HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Côte d'Or.

Aurélie Bertaut1, Pascal Chavanet, Serge Aho, Karine Astruc, Serge Douvier, Isabelle Fournel.   

Abstract

OBJECTIVES: To assess human papillomavirus prophylactic vaccine coverage among a representative population of French girls, aged 14 years and above, attending middle and high schools, and to determine factors associated with the initiation and completion of the vaccination protocol. STUDY
DESIGN: This cross-sectional study, designed with cluster sampling, was conducted from October 2010 to May 2011, in 29 schools in the department of Côte d'Or, France. The schools were randomized according to their status (public or private) and location (rural or urban). Two classes per level were then included. All analyses were stratified on age.
RESULTS: 948 questionnaires were collected (87.9% participation). Mean age was 15.2 years (SD=1.3), ranging between 14 and 19. Only 31.7% of 14-year-old girls and 61.4% of girls aged 15 and above initiated vaccination (one dose), and 7.8% of 14-year-old girls and 48.5% of girls aged 15 and above completed it (three doses). An urban school location and a physician's recommendation were independently associated with vaccination initiation in girls aged 14. In girls aged 15 and above, the parents' socioeconomic status, the family composition and a recommendation by a physician were independently associated with vaccination initiation. Once vaccination had been initiated, girls who attended private school, who belonged to families with higher outcomes, who lived with a single parent or who smoked were less likely to complete the vaccination protocol.
CONCLUSION: HPV prophylactic vaccine coverage in girls attending school in Côte d'Or appears to be low. Physicians play a major role in vaccine acceptance.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adolescent; CI; Cervical cancer; GP; HPV; OBJ GYN; OR; Obstetrician gynecologist; Papillomavirus vaccines; Prevention; Vaccination coverage; confidence interval; general practitioner; human papillomavirus; odds ratio

Mesh:

Substances:

Year:  2013        PMID: 23953913     DOI: 10.1016/j.ejogrb.2013.07.028

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  3 in total

Review 1.  Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review.

Authors:  K E Gallagher; E Kadokura; L O Eckert; S Miyake; S Mounier-Jack; M Aldea; D A Ross; D Watson-Jones
Journal:  BMC Public Health       Date:  2016-02-19       Impact factor: 3.295

Review 2.  Determinants in the Uptake of the Human Papillomavirus Vaccine: A Systematic Review Based on European Studies.

Authors:  Victoria Fernández de Casadevante; Julita Gil Cuesta; Lourdes Cantarero-Arévalo
Journal:  Front Oncol       Date:  2015-06-24       Impact factor: 6.244

3.  Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.

Authors:  Rengaswamy Sankaranarayanan; Priya Ramesh Prabhu; Michael Pawlita; Tarik Gheit; Neerja Bhatla; Richard Muwonge; Bhagwan M Nene; Pulikottil Okuru Esmy; Smita Joshi; Usha Rani Reddy Poli; Parimal Jivarajani; Yogesh Verma; Eric Zomawia; Maqsood Siddiqi; Surendra S Shastri; Kasturi Jayant; Sylla G Malvi; Eric Lucas; Angelika Michel; Julia Butt; Janki Mohan Babu Vijayamma; Subha Sankaran; Thiraviam Pillai Rameshwari Ammal Kannan; Rintu Varghese; Uma Divate; Shila Thomas; Geeta Joshi; Martina Willhauck-Fleckenstein; Tim Waterboer; Martin Müller; Peter Sehr; Sanjay Hingmire; Alka Kriplani; Gauravi Mishra; Sharmila Pimple; Radhika Jadhav; Catherine Sauvaget; Massimo Tommasino; Madhavan Radhakrishna Pillai
Journal:  Lancet Oncol       Date:  2015-12-02       Impact factor: 41.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.